Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
SIRT4, Glutamine Metabolism, and Liver Fibrosis
2026-08-11
The reference study identifies mitochondrial SIRT4 and GDH-dependent glutamine metabolism as a metabolic control point in activated hepatic stellate cells. Its in vitro and in vivo evidence suggests that suppressing glutamate conversion to α-ketoglutarate can reduce stellate-cell proliferation and slow liver fibrosis, while also highlighting important limits for translating the findings to other mitochondrial or metabolic interventions.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-08-11
4-Hydroxytamoxifen (SKU B6167) provides a DMSO-soluble estrogen receptor modulator for controlled in vitro and in vivo research workflows. It is suited to breast cancer research, prostate cancer research, apoptosis assay development, and cardiac myocyte calcium handling studies, but should not be selected for protocols requiring ethanol- or water-based solubilization.
-
WRN–MSI Synthetic Lethality in Colorectal Cancer
2026-08-10
The PNAS study identifies a p53–PUMA apoptotic mechanism underlying the selective dependence of mismatch repair-deficient, microsatellite-unstable colorectal cancer cells on Werner helicase. Its genetic, pharmacological, xenograft, and patient-derived models support WRN as a therapeutic vulnerability, while also showing that intact p53 is an important determinant of response.
-
FASN, Mitochondrial Priming, and ABT-263
2026-08-09
The reference study shows that fatty acid synthase (FASN) inhibition creates a redox-linked metabolic stress that increases mitochondrial apoptotic priming in cancer cells. This state enhances dependence on BCL-2 and improves responses to ABT-263 and venetoclax, providing a mechanistic rationale for combining metabolic inhibition with BH3 mimetics.
-
Protein A/G Magnetic Co-IP/IP Kit for BATF2–ATF3
2026-08-08
Use the Protein A/G Magnetic Co-IP/IP Kit to test BATF2–ATF3 association, ubiquitination-related regulation, and protein-complex changes in nucleus pulposus cell models. Magnetic separation supports a controlled path from lysate preparation to Western blot or mass spectrometry while reducing handling and degradation risks.
-
Foretinib: Separating Growth Arrest From Cell Death
2026-08-07
Foretinib and GSK1363089 are examined through a response-phenotyping framework that separates tumor cell growth inhibition from cell death. This guide translates kinase pharmacology and dissertation-based assay insights into better motility, invasion, and metastasis experiments.
-
Luminescent ATP Detection Assay Kit: Precision in Cancer Met
2026-08-07
Explore how the Luminescent ATP Detection Assay Kit empowers precise cellular ATP quantification in advanced cancer metabolism studies. Delve into expert analysis bridging assay innovation, glioblastoma glycolysis, and workflow optimization.
-
Trypsin: Precision Serine Protease for Cell Biology Research
2026-08-06
Trypsin is a serine protease enzyme with specificity for lysine and arginine residues, essential for proteolytic workflows in biomedical research. Its role extends from cell proliferation to membrane fusion and wound healing studies, with documented water solubility and strict storage requirements. APExBIO’s Trypsin (BA5744) offers validated performance for advanced experimental applications.
-
DAPI (hydrochloride): Precision DNA Visualization for Modern
2026-08-06
DAPI (hydrochloride) stands out as a premier DNA-specific fluorescent probe, delivering reliable nuclear labeling for both fixed and live cell applications. This guide details rigorous protocols, troubleshooting strategies, and advanced use-cases—empowering researchers to maximize clarity and reproducibility in histochemistry, cytometry, and cell cycle analysis.
-
L-THP Mitigates Methamphetamine-Induced Pulmonary Vascular R
2026-08-05
This study reveals that L-tetrahydropalmatine (L-THP) significantly attenuates methamphetamine-induced pulmonary vascular remodeling by modulating the CaSR-BMP2/mTOR signaling pathway. The findings clarify mechanistic links among CaSR activation, autophagy, and PASMC proliferation, providing a potential therapeutic avenue for drug-induced pulmonary arterial hypertension.
-
AMG 487: CXCR3 Antagonist Workflows in Inflammation Research
2026-08-05
AMG 487 empowers researchers to dissect CXCR3-driven macrophage polarization and autophagy with state-specific precision. This guide delivers stepwise protocols, key troubleshooting strategies, and cross-study insights to maximize experimental clarity in inflammation and acute lung injury models.
-
miR-18a/ALOXE3 Axis Regulates Ferroptosis and Migration in G
2026-08-04
This study reveals that miR-18a drives glioblastoma progression by downregulating ALOXE3, impairing ferroptosis, and enhancing tumor cell migration. The findings highlight a lipid metabolism–linked mechanism underlying glioblastoma aggressiveness, suggesting new therapeutic targets in the miR-18a/ALOXE3 pathway.
-
p53/PUMA-Mediated Synthetic Lethality via WRN Loss in MSI CR
2026-08-04
The reference study demonstrates that loss or inhibition of Werner (WRN) helicase triggers p53/PUMA-dependent apoptosis specifically in microsatellite instability (MSI) colorectal cancer cells. This mechanistic insight establishes WRN as a selective therapeutic target in mismatch repair-deficient, p53-wildtype cancers and informs ongoing development of DNA repair enzyme inhibitors in oncology.
-
ML216, BLM Helicase Inhibitor: Synthetic Lethality in Cancer
2026-08-03
ML216, a potent BLM helicase inhibitor from APExBIO, empowers researchers to interrogate DNA repair vulnerabilities and model synthetic lethality in cancer systems. This article details robust protocols, advanced applications, and troubleshooting strategies to maximize ML216’s impact in both cellular and in vivo assays.
-
Carvedilol Phosphate in Liver IRI: Mechanistic Insights & Mo
2026-08-03
This article frames Carvedilol Phosphate as a translational tool for hepatic ischemia–reperfusion injury (IRI) research, integrating recent mechanistic discoveries about Arrb2-mediated M2 macrophage polarization with actionable protocol guidance. We discuss solubility, workflow optimization, and the competitive landscape, providing a strategic vantage for researchers seeking reproducible, mechanistically grounded IRI models.